Cerebrovascular disease is not only the third largest cause of death in Canada, it is also associated with substantial functional morbidity after an event. In 2013, over 400,000 Canadians were living with the disabling effects of a stroke, most of which were due to ischemic injury. Extracranial internal carotid artery embolic events account for about 10%–15% of all strokes. Symptoms usually occur because of atherosclerotic plaque rupture in the internal carotid artery and embolization of plaque particles to the brain, which leads to transient or persistent ischemia in a specific anatomic area and related neurologic symptoms.

Population-based studies have suggested a high risk of recurrent transient ischemic attack (TIA) or stroke after an index event from a moderate to severe stenosis of the extracranial internal carotid artery, ranging from 10% to 20% within the next 90 days. Subsequently, a systematic review and meta-analysis found that most of these events occurred within the first 48 hours to 7 days, which suggests that risk is front loaded, and, consequently, an imperative to identify urgently and treat these patients at high risk to avoid the devastating consequences of a future stroke event. Management of symptomatic extracranial internal carotid artery stenosis, both medical and surgical, is aimed at reducing the likelihood that further plaque debris will embolize to the brain (Figure 1).

We review the medical and surgical management of patients with symptomatic extracranial internal carotid artery stenosis.

What are the clinical features of a transient ischemic attack or minor stroke related to internal carotid artery stenosis?

Symptoms and signs of a localized neurologic deficit are the hallmark of a TIA or minor stroke event. Global or bilateral symptoms and those that are not localized to a specific part of the brain are unlikely to be associated with an extracranial internal carotid artery plaque rupture (Box 2). It is outside the scope of this article to discuss these other diagnoses in detail.

What medical treatment should be started for acute transient ischemic attack or nondisabling strokes?

The current aim of medical treatment for the management of symptomatic extracranial internal carotid artery stenosis is to reduce the likelihood of further embolic events originating from the internal carotid artery plaque. Medical management aims to prevent further events until the carotid lesion can be treated and, secondarily, to manage risk factors that are common to cardiac atherosclerotic disease and thereby reduce the risk of future cardiac ischemic events. The 2 mainstays of acute management are antiplatelet agents and statin therapy. Long-term risk factor management — not discussed here — includes assistance with smoking cessation, diet and lifestyle educational interventions, glucose and cholesterol control, and management of hypertension.

Antiplatelet treatment

Treatment options include single antiplatelet versus dual antiplatelet regimens, unfractionated heparin or full anticoagulation, or a combination of modalities. Monotherapy with a single antiplatelet agent has been the mainstay of treatment for years. A 2016 meta-analysis showed that early initiation of acetylsalicylic acid (ASA) alone after a TIA or ischemic stroke reduced subsequent events by 60%.5

However, 2 recent large randomized controlled trials (RCTs) investigated dual-antiplatelet treatment in patients with acute symptoms of ischemic stroke. The investigators from the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial compared the benefit of dual antiplatelet therapy over ASA alone in the acute management of over 5000 patients in China with nondisabling stroke or high-risk TIA.6 A dual antiplatelet regimen of clopidogrel, administered with a 300 mg initial dose followed by 75 mg daily for 90 days, added to ASA (75 mg daily) given over the first 21 days, reduced the likelihood of stroke events over 90 days compared with ASA alone (hazard ratio 0.68, 95% [confidence interval] CI 0.57–0.81). No increased bleeding events were noted in the group receiving dual-antiplatelet treatment. However, these findings cannot be generalized beyond the Chinese population.

More recently, the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial investigators compared a 600 mg loading dose of clopidogrel followed by 75 mg per day with ASA (50–325 mg/d) versus ASA alone in an international population of 4881 patients.7 The duration of treatment studied in the POINT trial exceeded that in the CHANCE trial, and the investigators looked at ischemic events after 90 days of treatment rather than 21 days. Although there was a significant reduction in major ischemic events at 90 days in the dual-antiplatelet arm (5% v. 6.5%), the POINT trial was stopped early because of increased major hemorrhage occurring in patients in the dual-antiplatelet arm (0.9% v. 0.4%). Most of the bleeding events were nonintracranial, with no difference in death from such events in either arm.

An important limitation of the POINT trial was that patients who underwent a carotid intervention were excluded. The risks of surgery among patients on dual antiplatelet therapy must be considered; some surgeons have concerns about the potential for neck hematoma owing to bleeding after carotid artery endarterectomy. This is especially true, given that the POINT trial excluded these patients, which may mitigate some of the benefits seen in this study.

---

**Box 1: Evidence used in this review**

Given the large number of carotid-related publications, we conducted 4 question-specific narrative searches of PubMed that reflected our 4 main questions. There were no language or time restrictions. We focused our conclusions on randomized controlled trials, large observational cohorts, Canadian data (where available) and meta-analyses. A total of 88 articles were identified. We added additional articles for review. The search strategy for the literature review is listed in Appendix 1.

**Box 2: Signs or symptoms possibly or unlikely to be related to an extracranial internal carotid artery embolic event**

<table>
<thead>
<tr>
<th>Signs or symptoms suggestive of an extracranial ICA event</th>
<th>Signs or symptoms unlikely to be related to an extracranial ICA event</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Unilateral extremity motor or sensory impairment (transient, fluctuating or persistent)</td>
<td>• Dizziness</td>
</tr>
<tr>
<td>• Monocular vision loss</td>
<td>• Vertigo</td>
</tr>
<tr>
<td>• Acute speech deficit or change</td>
<td>• Bilateral visual disturbances</td>
</tr>
<tr>
<td>• Facial droop</td>
<td>• Headache</td>
</tr>
<tr>
<td>• Bilateral extremity motor or sensory impairment</td>
<td>• Ataxia</td>
</tr>
</tbody>
</table>

Note: ICA = internal carotid artery.

*Symptoms of a carotid event are related to the specific area of the brain that is affected, resulting in a focal neurologic deficit.*
The findings from the CHANCE and the POINT trials suggest that dual-antiplatelet therapy may reduce the risk of further neurologic events in symptomatic patients with a minor stroke or high-risk TIA more than treatment with ASA alone. Differences between the trials in observed bleeding events may be attributed to the longer duration of dual-antiplatelet therapy in the POINT trial (90 d v. 21 d). The intensity of the loading dose used by the POINT trial investigators could be a concern; however, the increased bleeding risk occurred between 8 and 90 days and not during the first 7 days in the POINT trial.

Because dual-antiplatelet therapy in the acute period after a nondisabling stroke or TIA has been shown to reduce rates of recurrent stroke, this approach should be considered at least for 21 days. Use of short-term, early dual-antiplatelet therapy is supported by the 2018 Canadian Stroke Best Practice Recommendations for the Secondary Prevention of Stroke, the 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke from the American Heart Association/American Stroke Association and the 2017 European carotid guidelines as Level A, B and C recommendations, respectively.

**Statin therapy**

The long-term benefit of statins for patients at risk for atherosclerotic events is well-established, including after an ischemic stroke event. Since 2002, after the publication of findings from the Medical Research Council (MRC)/British Heart Foundation (BHF) Heart Protection Study, statins have been used to decrease mortality in patients at risk for cardiovascular, peripheral arterial or stroke events. The pleiotropic effect of statins is well documented; they appear to confer benefits beyond their lipid-lowering effect. A 2012 meta-analysis of individual patient data from 27 RCTs found a significant dose-dependent benefit of statin use in patients at risk for vascular events. Every 1 mmol/L reduction in low-density lipoprotein (LDL) was associated with about a 25% reduction in cardiovascular mortality, and an overall 15% reduction in risk of stroke events. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial investigators evaluated the effect of an aggressive lipid-lowering regimen of high-dose atorvastatin (80 mg daily) in patients 1–6 months after a stroke or TIA and found a relative risk reduction of 33% in fatal and nonfatal strokes over almost 5 years.

There are, however, limited data on the effectiveness of statin treatment immediately after TIA or nondisabling strokes. A retrospective review of symptomatic patients who underwent carotid artery endarterectomy in Western Canada found that use of a statin reduced in-hospital death by 75% and ischemic stroke or death by 45% (adjusted odds ratios 0.25, 95% CI 0.07–0.90, and 0.55, 95% CI 0.32–0.95, respectively). A 2005 retrospective study estimated that use of preoperative statins reduced rates of perioperative stroke by 73% compared with no statin use (1.3% v. 4.5%). However, no evidence from RCTs is available to support the idea that immediate statin initiation after TIA or nondisabling symptomatic stroke improves early outcomes.

Recent Canadian, American and European guidelines recommend starting treatment with a statin for long-term prevention of stroke, myocardial infarction (MI) and other vascular events in patients with recently symptomatic ischemic neurologic events. Currently, in contrast to the recommendations for starting antiplatelet therapy, there are no Level A recommendations (i.e., based on evidence from RCTs) for immediate or intensive initiation of statin therapy for reducing early stroke events.

**When should carotid intervention occur?**

“Carotid intervention” includes carotid artery endarterectomy and carotid artery stenting. Decades ago, intervention for secondary prevention after an embolic extracranial stroke of internal carotid artery origin was delayed for 4–8 weeks to allow the brain to “recover.” This was done in the hopes of avoiding consequences of early reperfusion such as cerebral edema and hemorrhage. However, excessive delay to intervention resulted in a prohibitively large number of recurrent stroke events.

A 2004 pooled analysis of data from 2 large RCTs showed a clear benefit for carotid artery endarterectomy in patients with recent symptoms from extracranial internal carotid artery stenoses. The number needed to treat was 6 for patients with a severe (70%–99%) ipsilateral carotid stenosis and 13 for those with moderate (50%–69%) stenosis.

**Emergent treatment**

The benefit of carotid intervention has been shown to be based on several factors, including degree of stenosis, patient sex and time to intervention, with earlier intervention — within 2 weeks — being associated with a greater secondary preventative benefit, and a longer delay associated with less benefit to the patient. This evidence underpinned previous recommendations by national guidelines that advocated intervention within 14 days.

However, more recent evidence has shown a high risk of recurrent events within the first few days to weeks after a TIA or minor stroke without intervention. A 2015 systematic review estimated the risks of a repeat neurologic event to be 6% within 2–3 days and as high as 19.5% within 7 days of TIA or minor stroke related to stenosis of the extracranial internal carotid artery. This has led to a shift to more urgent scheduling of carotid interventions in patients with internal carotid artery–related stroke or TIA and a recent change to the Canadian guideline.

The 2018 Canadian Stroke Best Practice Recommendations now state that patients with a TIA or nondisabling stroke, who present with “transient, fluctuating or persistent unilateral motor weakness or speech disturbance/aphasia or ocular symptoms,” should undergo carotid intervention as soon as possible if they have moderate to severe stenosis of the extracranial internal carotid artery (50%–99%), ideally within the first few days of presentation when reasonable. Such patients should not be discharged home but rather be admitted for emergent work-up, medical treatment and expedited intervention in an effort to prevent another — potentially disabling — embolic stroke event. Patients with a TIA or minor stroke and severe extracranial internal carotid artery stenosis should be treated with similar urgency to patients with an MI or unstable angina.
Controversy

Many studies that assessed carotid artery endarterectomy performed within 48 hours of symptom onset found acceptable risks of perioperative stroke and death, whereas the Carotid Alarm Study found higher risk of complications if intervention was performed within 48 hours. A 2018 meta-analysis of RCTs and observational studies that compared stroke rates between very urgent (<48 h from symptom onset) and urgent endarterectomy (>48 h) found higher stroke rates after very urgent endarterectomy.

Although there is no RCT evidence to guide timing of early carotid intervention, there may be a benefit to waiting beyond 48 hours after symptom onset to minimize the risk of postoperative stroke; however, beyond that, surgery should occur as soon as possible and ideally within the first few days postevent. The 2018 American stroke guideline recommends that carotid intervention occur between 48 hours and 7 days of symptom onset.

Regardless of the timing to intervention, the timing to first assessment by a specialist in carotid intervention should be considered urgent, to hasten creation of a patient-specific treatment plan aimed at reducing further embolic events.

Special considerations

There are 2 specific subgroups of patients that arguably should not receive carotid intervention within the guideline-recommended time period. At 1 end of the spectrum, patients with crescendo TIAs have a devastatingly high risk of another stroke event early on and should undergo carotid intervention within 24 hours. At the other end of spectrum certain patients, including those with a large territory of ischemic brain (>1/3 of the middle cerebral artery territory) or evidence of ischemic hemorrhage, may benefit from purposeful delay to carotid intervention (>2–4 wk) because they are at elevated risk of postintervention cerebral reperfusion, hemorrhage and subsequent complications, and these should be weighed against the risk of recurrent stroke. Both of these recommendations are supported in the 2017 European guideline but are not specifically addressed in the 2018 Canadian or American guidelines.

Should patients undergo carotid artery endarterectomy or stenting?

The large Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST), which compared carotid artery endarterectomy to carotid artery stenting, found that the aggregate outcome of stroke, MI or death from any cause during the periprocedural period or any ipsilateral stroke within 4 years after random assignment was similar for both groups. However, if the goal of intervention is stroke prevention, then the compound end point is somewhat misleading. When assessed for stroke outcomes, patients who received carotid artery stenting had double the risk of periprocedural stroke or death compared with those who received carotid artery endarterectomy (4.1% v. 2.3%). In the long term, the risks of ipsilateral stroke were similar in both groups. However, carotid artery stenting did show a reduced rate of periprocedural MI compared with endarterectomy (1.1% v. 2.3%) and fewer local complications. In a 2018 comparison of more than 15 000 carotid interventions performed in Ontario, carotid artery endarterectomy was associated with a 55% lower risk of adverse events when compared with carotid artery stenting.

Carotid artery stenting may have a role in the management of some patients (e.g., those with unstable cardiac or respiratory conditions, or patients with high–carotid artery bifurcation or long lesions) who are less likely to do well with carotid artery endarterectomy. However, evidence suggests that the best choice of carotid intervention remains carotid artery endarterectomy for all symptomatic patients with moderate to severe carotid artery stenosis. A pooled analysis of the 3 largest trials examining carotid artery endarterectomy versus carotid artery stenting found that the highest relative risk of periprocedural stroke events (stenting v. endarterectomy) occurred in the first 7 days after the procedure, further supporting the choice of endarterectomy over stenting, since carotid intervention is usually undertaken more urgently now.

Conclusion

Symptomatic extracranial moderate to severe carotid artery stenosis, if left untreated, can have devastating consequences. Given the high risk of further neurologic events in the period immediately following the initial presentation, urgent admission is warranted to ensure early assessment by a specialist in carotid disease, with a view to urgent carotid intervention — ideally carotid artery endarterectomy for patients with more than 50% symptomatic extracranial internal carotid artery stenosis. Physicians should not be falsely reassured if the index event was transient and assume that early symptom resolution implies urgent intervention is not required, because the resolution of symptoms does not predict a more favourable profile.

The new Canadian guideline recommends carotid intervention within the first few days after a nondisabling stroke or TIA. Dual antiplatelet therapy is warranted immediately but should be limited to a short period (less than 21 days) because of the risk of bleeding. Statin therapy should be considered for secondary prevention; however, its benefit for reduction in early recurrent events is not clear.

References


